Literature DB >> 1054305

Altered membrane sodium transport and the presence of a plasma ouabain-like inhibitory factor in acute myeloid leukaemia.

M A Mir, H Bobinski.   

Abstract

1. Sodium transport studies were performed in erythrocytes from normal subjects and from patients with acute myeloid leukaemia. Sodium influx and efflux rates were increased in erythrocytes from leukaemic patients. 2. The ouabain-sensitive component of sodium efflux was increased in leukaemic erythrocytes. 3. The high sodium efflux from leukaemic erythrocytes was decreased when the incubation media contained leukaemic plasma, suggesting the presence of an ouabain-like factor in the plasma. Paired experiments failed to show the presence of a similar factor in normal plasma. 4. Leukaemic erythrocytes showed a significantly greater ouabain uptake than the normal cells. 5. The results are discussed in relation to the wide-spread electrolyte disturbances in acute myeloid leukaemia.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1054305     DOI: 10.1042/cs0480213

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  5 in total

1.  Inhibitin: a specific inhibitor of sodium/sodium exchange in erythrocytes.

Authors:  K Morgan; R C Brown; G Spurlock; K Southgate; M A Mir
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

2.  Hypokalaemia in leukaemia.

Authors:  A A Nanji; J Denegri
Journal:  Postgrad Med J       Date:  1981-08       Impact factor: 2.401

3.  Isolation of a sodium transport inhibitory factor, inhibitin, from cultured leukemic promyelocytes.

Authors:  K Morgan; M A Mir
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

4.  Lysozyme: a brief review.

Authors:  M A Mir
Journal:  Postgrad Med J       Date:  1977-05       Impact factor: 2.401

5.  Granulocyte function in myeloblastic leukaemia.

Authors:  P M Wilkinson; C Sumner; I W Delamore; C G Geary; G R Milner
Journal:  Br J Cancer       Date:  1975-11       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.